ESMO 2025, Berlin, Germany

Host: Sidney Ocanagil-Tunstall

Recorded on 19th October 2025

Amidst the hustle and bustle of one of world’s largest oncology conferences Pathology News sat down with Felix Faber, CEO and Founder of Mindpeak, and Dr Patrick Frey, Head of Precision Medicine, to discuss how multiplex immunofluorescence (mIF) and artificial intelligence are influencing biomarker discovery and diagnostic development.

The discussion explores how advances in multiplex imaging and AI are helping researchers extract richer, more reproducible data from tissue samples. Between them explaining how multiplex immunofluorescence enables the simultaneous visualisation of numerous biomarkers within a single slide — providing a detailed view of cellular interactions and the tumour microenvironment that traditional IHC cannot capture.

They also touch on the importance of interoperability, the emergence of foundation models capable of supporting small-object detection, and the potential to accelerate biomarker discovery through faster, standardised workflows.

The conversation closes with a look ahead: how scalable, high-throughput multiplex workflows could soon bridge research and clinical practice, and why collaboration across industry and academia will be essential to bringing these capabilities into routine oncology diagnostics.